Abstract
Background
Therapeutic inertia is a key barrier to blood pressure (BP) control.
Objectives
To identify demographic, clinical, and health system factors associated with treatment intensification for uncontrolled hypertension including in-person medical office versus team-based BP clinic encounters.
Design and Participants
This mixed-methods study included a quantitative analysis of electronic health records and 11 semi-structured provider interviews from Kaiser Permanente Southern California (KPSC). This study included KPSC adults with hypertension and uncontrolled BP (≥ 140/ ≥ 90 mm Hg) during office encounters in 2018, followed for 6 months.
Main Measures
Treatment intensification defined as increasing dose or adding a new class of antihypertensive medications, and 6-month BP reduction associated with treatment intensification. Multivariable regression analyses were used to identify factors associated with treatment intensification. Themes around barriers and facilitators of treatment intensification were developed from the provider interviews.
Results
Among 221,519 patients with uncontrolled BP, 29% received an increased dose or added medications. Mean (SD) 6-month systolic BP reductions were 16.6 (14.3) mm Hg and 11.7 (13.5) mm Hg for those with treatment intensification versus not (p < 0.01). Older age (OR for age ≥ 76 vs 18–55 years = 0.68; 95% CI 0.65, 0.71) and having diabetes (OR = 0.86; 95% CI 0.84, 0.88) were associated with lower odds of treatment intensification; while team-based BP clinic encounters were associated with higher odds of treatment intensification (OR = 1.23; 95% CI 1.20, 1.27). Provider interviews showed concerns about side effects, medication nonadherence, and shared decision-making are key factors in decisions to intensify therapy.
Conclusions
Less than one-third of patients with uncontrolled BP received increased hypertension medication doses, with more frequent intensifications in team-based BP clinics. Targeted interventions to address the identified barriers are needed to improve BP control.
Topic
JGIM
Author Descriptions
Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
Jaejin An PhD, Teresa N. Harrison SM, Liang Ni MPH, Janet Mora Marquez BS & Kristi Reynolds PhD
Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA
Jaejin An PhD, Jeffrey W. Brettler MD & Kristi Reynolds PhD
Kaiser Permanente Panorama City Medical Center, Panorama City, CA, USA
Angeline L. Ong-Su MD
Kaiser Permanente West Los Angeles Medical Center, Los Angeles, CA, USA
Jeffrey W. Brettler MD
Improving Health Outcomes, American Medical Association, Chicago, IL, USA
Gregory Wozniak PhD & Michael Rakotz MD
Improving Health Outcomes, American Medical Association, Greenville, SC, USA
Brent Egan MD
Share
Related Articles
Understanding the Causes of Nonadherence to Chronic Medications Among Patients With Cancer and Multimorbidity: A Qualitative Study
Abstract Background When patients with multimorbidity (≥ 2 chronic diseases) are diagnosed with…
Characteristics of Restraint Use on Inpatient Medical/Surgical and Psychiatric Units at a Tertiary Care County Hospital
Abstract Background Racism contributes to worse patient care and health outcomes in…